Research: Eli Lilly and Company

Articles found below have been submitted through various PR and news sources and don’t necessary reflect the views of SalesTrax or its employees.

Pharmaceutical Business Review

2009-08-19 08:03
Eli Lilly Reports Preliminary Phase III GJAD Study Results
Could reduce the risk of vertebral fracture and invasive breast cancer in postmenopausal women

2009-08-06 08:03
Daiichi Sankyo, Eli Lilly Launch Effient In US
Helps keep blood platelets from clumping together and developing a blockage in an artery

2009-06-16 04:03
Eli Lilly Announces New Drug Discovery Initiative
Lilly' Phenotypic Drug Discovery Initiative to use indigeneously developed disease-state assays and secure web portal

2009-06-09 12:04
Eli Lilly Selects ICON To Manage Its Clinical Trial Site Set Up And Monitoring In Europe
Eli Lilly and Company (Eli Lilly) has selected ICON plc (ICON) to manage clinical trial site set up and monitoring in Europe for Eli Lilly managed studies. The agreement, which is subject to the relevant employee consultation processes, is a continuation of Eli Lilly?s ongoing transformation of its research and development organization and follows Eli Lilly?s selection of ICON to manage its clinical data management business outside of the US.

2009-06-05 04:03
Eli Lilly Resubmits Cymbalta Supplemental New Drug Application To FDA
Application is supported by studies in diabetic peripheral neuropathic pain and fibromyalgia

2009-06-01 12:03
Lilly's Gemzar Successful In Improving Progression-Free Survival In Cervical Cancer Patients
Eli Lilly has announced that phase III trial data showed the addition of Gemzar (gemcitabine HCl for injection) to the current standard of care, provided a statistically significant increase in progression-free survival at three years for women with locally advanced cervical cancer.